

# Mu Moreno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/211254/publications.pdf>

Version: 2024-02-01

46  
papers

2,230  
citations

279487

23  
h-index

253896

43  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Biomarkers of Myocardial Fibrosis. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2449-2456.	1.2	196
2	Oxidative stress and vascular remodelling. <i>Experimental Physiology</i> , 2005, 90, 457-462.	0.9	129
3	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2021, 18, 479-498.	6.1	128
4	Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 251-260.	1.2	127
5	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , 2018, 72, 549-558.	1.3	123
6	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. <i>Diabetes</i> , 2006, 55, 209-215.	0.3	121
7	Gene expression profiling in whole blood of patients with coronary artery disease. <i>Clinical Science</i> , 2010, 119, 335-343.	1.8	121
8	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. <i>Journal of Hypertension</i> , 2004, 22, 2169-2175.	0.3	92
9	Functional Effect of the p22 phox $\Delta$ 930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. <i>Hypertension</i> , 2004, 44, 163-169.	1.3	89
10	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. <i>FEBS Letters</i> , 2003, 542, 27-31.	1.3	86
11	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of the p22phox Gene in Hypertension. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1327-1336.	2.5	86
12	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. <i>Journal of Hypertension</i> , 2006, 24, 1299-1306.	0.3	83
13	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 587-593.	1.1	82
14	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. <i>Hypertension</i> , 2019, 73, 602-611.	1.3	78
15	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. <i>Cerebrovascular Diseases</i> , 2007, 24, 24-29.	0.8	65
16	NADPH Oxidase-Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1452-1457.	1.1	62
17	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. <i>Journal of Hypertension</i> , 2017, 35, 853-861.	0.3	58
18	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1398-1410.	1.2	54

#	ARTICLE	IF	CITATIONS
19	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. <i>Kidney International</i> , 2005, 68, S71-S75.	2.6	45
20	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. <i>Journal of Hypertension</i> , 2010, 28, 1944-1950.	0.3	44
21	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. <i>Cardiovascular Research</i> , 2011, 92, 247-255.	1.8	42
22	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. <i>Hypertension</i> , 2019, 73, 820-828.	1.3	41
23	A novel CYBA variant, the 675A/T polymorphism, is associated with essential hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1620-1626.	0.3	34
24	A Synthetic Peptide from Transforming Growth Factor- $\beta$ Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1607-1618.	2.5	21
25	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. <i>Scientific Reports</i> , 2017, 7, 41865.	1.6	21
26	The Hypertensive Myocardium. <i>Medical Clinics of North America</i> , 2017, 101, 43-52.	1.1	21
27	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020, 40, 223-236.	0.2	21
28	Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007. <i>Atherosclerosis</i> , 2010, 211, 271-277.	0.4	18
29	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. <i>Free Radical Research</i> , 2017, 51, 389-396.	1.5	18
30	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. <i>Hypertension</i> , 2014, 63, 468-474.	1.3	16
31	Biomarker-based assessment of collagen crosslinking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 321-331.	2.9	16
32	Blockade of TGF- $\beta$ Signalling Inhibits Cardiac NADPH Oxidase Overactivity in Hypertensive Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-8.	1.9	14
33	Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease. <i>BMC Nephrology</i> , 2013, 14, 173.	0.8	14
34	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. <i>Clinical Science</i> , 2013, 125, 291-300.	1.8	14
35	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. <i>Clinical Science</i> , 2009, 116, 233-240.	1.8	8
36	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1231-1240.	0.8	8

#	ARTICLE	IF	CITATIONS
37	CYBA gene variants as biomarkers for coronary artery disease. <i>Drug News and Perspectives</i> , 2010, 23, 316.	1.9	8
38	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020, 40, 223-236.	0.2	7
39	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2010, 28, 2219-2226.	0.3	6
40	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 1467-1474.	0.9	5
41	Functional significance of single nucleotide polymorphisms within the 5' flanking region of $\beta$ 2-adrenergic receptor gene. <i>Journal of Hypertension</i> , 2006, 24, 2473-2474.	0.3	3
42	Functional Genomics of the Oxidative Stress Pathway. <i>Current Hypertension Reviews</i> , 2007, 3, 156-165.	0.5	3
43	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. <i>Cardiovascular Research</i> , 2019, 115, 696-698.	1.8	2
44	Tu-P7:274 Phagocytic NADPH oxidase overactivity associates with plasma levels of matrix metalloproteinase-9 in subjects free of clinical atherosclerotic disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 245.	1.2	0
45	GENE EXPRESSION PROFILING IN MONONUCLEAR CELLS DEMONSTRATES UP-REGULATION OF PRO-INFLAMMATORY AND ADHESION RELATED GENES CORONARY ARTERY DISEASE. <i>Atherosclerosis</i> , 2009, 207, e6-e7.	0.4	0
46	Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]. <i>FEBS Letters</i> , 2010, 584, 4709-4709.	1.3	0